Truist Securities Downgrades Funko to Hold, Lowers Price Target to $13

Truist Securities analyst Michael Swartz downgrades Funko (NASDAQ:FNKO) from Buy to Hold and lowers the price target from $26 to $13.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Truist Securities analyst Michael Swartz downgrades Funko (NASDAQ:FNKO) from Buy to Hold and lowers the price target from $26 to $13.

Barclays Maintains Equal-Weight on Rockwell Automation, Raises Price Target to $250

By Benzinga Newsdesk

January 27, 8:57 AM

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:ROK) with a Equal-Weight and raises the price target from $220 to $250.

ROK

RBC Capital Maintains Outperform on NextEra Energy Partners, Lowers Price Target to $87

By Benzinga Newsdesk

January 30, 8:49 AM

RBC Capital analyst Shelby Tucker maintains NextEra Energy Partners (NYSE:NEP) with a Outperform and lowers the price target from $89 to $87.

NEP

Evercore ISI Group Downgrades Enterprise Prods Partners to In-Line

By Benzinga Newsdesk

April 4, 6:11 AM

Evercore ISI Group analyst Todd Firestone downgrades Enterprise Prods Partners (NYSE:EPD) from Outperform to In-Line.

EPD

FDA
News

VistaGen Therapeutics Reports New Preclinical Mechanism Of Action Data; Co Says Data Supports PH94B’s Potential Anti-Anxiety Activity Via Peripheral Nasal Neurons Without Entry Into Brain

By Benzinga Newsdesk

October 5, 8:03 AM

VistaGen Therapeutics (NASDAQ:VTGN), a biopharmaceutical company developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central

VTGN

Truist Securities Downgrades Funko to Hold, Lowers Price Target to $13

Related Posts

Barclays Maintains Equal-Weight on Rockwell Automation, Raises Price Target to $250

RBC Capital Maintains Outperform on NextEra Energy Partners, Lowers Price Target to $87

Evercore ISI Group Downgrades Enterprise Prods Partners to In-Line

VistaGen Therapeutics Reports New Preclinical Mechanism Of Action Data; Co Says Data Supports PH94B’s Potential Anti-Anxiety Activity Via Peripheral Nasal Neurons Without Entry Into Brain